Astrazeneca (AZN) Interest Expenses (2009 - 2026)

Astrazeneca (AZN) has reported Interest Expenses for 18 consecutive years, with -$393.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses fell 12.61% year-over-year to -$393.0 million; the TTM figure through Mar 2026 stood at -$1.8 billion (down 4.29% YoY), while the FY2025 annual figure was $1.7 billion, down 2.76% from the prior year.
• Interest Expenses came in at -$393.0 million for Q1 2026 at Astrazeneca, up from -$484.0 million in the prior quarter.
• The five-year high for Interest Expenses was -$311.0 million in Q2 2022, with the low at -$484.0 million in Q4 2025.
• Average Interest Expenses over 5 years is -$401.2 million, with a median of -$413.0 million recorded in 2024.
• Across the five-year window, Interest Expenses plunged 38.59% in 2023 and increased 15.5% in 2025, its largest moves.
• Year by year, Interest Expenses stood at -$360.0 million in 2022, then declined by 23.61% to -$445.0 million in 2023, then increased by 3.6% to -$429.0 million in 2024, then dropped by 12.82% to -$484.0 million in 2025, then climbed by 18.8% to -$393.0 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered -$393.0 million, -$484.0 million, and -$434.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.